Temodar — CareFirst (Caremark)

Initial criteria

• Authorization may be granted for treatment of high-risk neuroblastoma when used in combination with irinotecan, dinutuximab, and sargramostim.

Reauthorization criteria

• Authorization may be renewed if there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval duration

12 months